Total Number of Communication Reports: 7
Monthly communication reports in the last 6 months: 0
Subject matters | Details | Categories |
---|---|---|
Health
|
Food and Drugs Act, specifically with respect to the approval, regulation and life-cycle management of therapeutic products
|
Policies or Program
|
Health
|
Health Canada's Special Access Program (SAP) and associated regulations and guidelines
|
Regulation, Policies or Program
|
Health
|
Health Canada Regulatory Review of Drugs and Devices, including potential regulatory reforms with respect to drugs for rare diseases
|
Policies or Program
|
Health
|
Health system policies with respect to pharmaceuticals, including drugs for rare diseases
|
Policies or Program
|
Economic Development, Industry, Intellectual Property, Research and Development, Science and Technology
|
Innovation agenda led by Innovation, Science and Economic Development Canada, particularly with respect to the life sciences industry
|
Policies or Program
|
Health
|
Patented Medicine Prices Review Board (PMPRB) guidelines with respect to non-excessive pricing of patented medicines
|
Policies or Program
|
Health
|
Patented Medicine Prices Review Board (PMPRB) regulations with respect to non-excessive pricing of patented medicines
|
Regulation
|
Address:
9131 Keele Street, Unit 4A
Vaughn, ON L4K 0G7
Canada
Telephone number:
224-383-3000
Matt McCarthy, General Manager
Horizon Therapeutics Canada is not a coalition.
The activities of Horizon Therapeutics Canada are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Horizon Therapeutics Canada does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Stephen Sampson | Public offices held
Firm: Global Public Affairs